Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1994 Nov;94(5):2045–2050. doi: 10.1172/JCI117558

Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion.

B Ludvik 1, M Clodi 1, A Kautzky-Willer 1, M Schuller 1, H Graf 1, E Hartter 1, G Pacini 1, R Prager 1
PMCID: PMC294639  PMID: 7962550

Abstract

To elucidate the metabolism of islet amyloid polypeptide (IAPP) with respect to a possible renal elimination we investigated IAPP levels in 20 lean, nondiabetic patients with renal failure maintained on chronic hemodialysis (HD) and in 20 healthy controls. The basal levels of IAPP were significantly higher in uremic patients than in controls (15.1 +/- 3.2 vs. 3.2 +/- 0.2 pM, P < 0.001) suggesting renal excretion of IAPP. To investigate the impact of chronically elevated levels of endogenous IAPP on insulin secretion and insulin sensitivity, a frequently sampled intravenous glucose tolerance test (FSIGT) was performed in a subset of patients on hemodialysis and in age-matched healthy controls (C) and obese patients with normal (NGT) and with impaired glucose tolerance (IGT). Insulin sensitivity index (SI) was 8.7 +/- 1.5 in C (P < 0.05 vs. NGT, P < 0.01 vs. IGT), 5.4 +/- 0.9 in HD (P < 0.05 vs. IGT), 3.1 +/- 1.0 in NGT, and 2.0 +/- 0.5 in IGT. First phase insulin secretion was increased in patients on HD compared with those of several control groups. The results of this study therefore indicate a renal route of metabolism of IAPP. Increased endogenous circulating IAPP levels over a long period of time do not lead to a decrease in insulin release in patients on HD and do not cause the insulin resistance commonly seen in obesity and diabetes. Increased levels of circulating IAPP therefore are not likely to be a pathogenetic factor in the development of non-insulin-dependent diabetes mellitus (NIDDM).

Full text

PDF
2045

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akmal M., Massry S. G., Goldstein D. A., Fanti P., Weisz A., DeFronzo R. A. Role of parathyroid hormone in the glucose intolerance of chronic renal failure. J Clin Invest. 1985 Mar;75(3):1037–1044. doi: 10.1172/JCI111765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bretherton-Watt D., Gilbey S. G., Ghatei M. A., Beacham J., Macrae A. D., Bloom S. R. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab. 1992 May;74(5):1032–1035. doi: 10.1210/jcem.74.5.1569151. [DOI] [PubMed] [Google Scholar]
  3. Clark A., Cooper G. J., Lewis C. E., Morris J. F., Willis A. C., Reid K. B., Turner R. C. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet. 1987 Aug 1;2(8553):231–234. doi: 10.1016/s0140-6736(87)90825-7. [DOI] [PubMed] [Google Scholar]
  4. Cooper G. J., Leighton B., Dimitriadis G. D., Parry-Billings M., Kowalchuk J. M., Howland K., Rothbard J. B., Willis A. C., Reid K. B. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7763–7766. doi: 10.1073/pnas.85.20.7763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cooper G. J., Willis A. C., Clark A., Turner R. C., Sim R. B., Reid K. B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A. 1987 Dec;84(23):8628–8632. doi: 10.1073/pnas.84.23.8628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DeFronzo R. A., Alvestrand A., Smith D., Hendler R., Hendler E., Wahren J. Insulin resistance in uremia. J Clin Invest. 1981 Feb;67(2):563–568. doi: 10.1172/JCI110067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fox N., Schrementi J., Nishi M., Ohagi S., Chan S. J., Heisserman J. A., Westermark G. T., Leckström A., Westermark P., Steiner D. F. Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS Lett. 1993 May 24;323(1-2):40–44. doi: 10.1016/0014-5793(93)81444-5. [DOI] [PubMed] [Google Scholar]
  8. Graf H., Prager R., Kovarik J., Luger A., Schernthaner G., Pinggera W. F. Glucose metabolism and insulin sensitivity in patients on chronic hemodialysis. Metabolism. 1985 Oct;34(10):974–977. doi: 10.1016/0026-0495(85)90148-9. [DOI] [PubMed] [Google Scholar]
  9. Hartter E., Svoboda T., Ludvik B., Schuller M., Lell B., Kuenburg E., Brunnbauer M., Woloszczuk W., Prager R. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 1991 Jan;34(1):52–54. doi: 10.1007/BF00404025. [DOI] [PubMed] [Google Scholar]
  10. Kahn S. E., D'Alessio D. A., Schwartz M. W., Fujimoto W. Y., Ensinck J. W., Taborsky G. J., Jr, Porte D., Jr Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes. 1990 May;39(5):634–638. doi: 10.2337/diab.39.5.634. [DOI] [PubMed] [Google Scholar]
  11. Kautzky-Willer A., Thomaseth K., Pacini G., Clodi M., Ludvik B., Streli C., Waldhäusl W., Prager R. Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia. 1994 Feb;37(2):188–194. doi: 10.1007/s001250050092. [DOI] [PubMed] [Google Scholar]
  12. Leighton B., Cooper G. J. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature. 1988 Oct 13;335(6191):632–635. doi: 10.1038/335632a0. [DOI] [PubMed] [Google Scholar]
  13. Ludvik B., Clodi M., Kautzky-Willer A., Capek M., Hartter E., Pacini G., Prager R. Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia. 1993 Jan;36(1):84–87. doi: 10.1007/BF00399099. [DOI] [PubMed] [Google Scholar]
  14. Ludvik B., Lell B., Hartter E., Schnack C., Prager R. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes. 1991 Dec;40(12):1615–1619. doi: 10.2337/diab.40.12.1615. [DOI] [PubMed] [Google Scholar]
  15. Lukinius A., Wilander E., Westermark G. T., Engström U., Westermark P. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia. 1989 Apr;32(4):240–244. doi: 10.1007/BF00285291. [DOI] [PubMed] [Google Scholar]
  16. Molina J. M., Cooper G. J., Leighton B., Olefsky J. M. Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes. 1990 Feb;39(2):260–265. doi: 10.2337/diab.39.2.260. [DOI] [PubMed] [Google Scholar]
  17. Mosselman S., Höppener J. W., Zandberg J., van Mansfeld A. D., Geurts van Kessel A. H., Lips C. J., Jansz H. S. Islet amyloid polypeptide: identification and chromosomal localization of the human gene. FEBS Lett. 1988 Nov 7;239(2):227–232. doi: 10.1016/0014-5793(88)80922-0. [DOI] [PubMed] [Google Scholar]
  18. Nagamatsu S., Carroll R. J., Grodsky G. M., Steiner D. F. Lack of islet amyloid polypeptide regulation of insulin biosynthesis or secretion in normal rat islets. Diabetes. 1990 Jul;39(7):871–874. doi: 10.2337/diab.39.7.871. [DOI] [PubMed] [Google Scholar]
  19. O'Brien T. D., Westermark P., Johnson K. H. Islet amyloid polypeptide (IAPP) does not inhibit glucose-stimulated insulin secretion from isolated perfused rat pancreas. Biochem Biophys Res Commun. 1990 Aug 16;170(3):1223–1228. doi: 10.1016/0006-291x(90)90524-q. [DOI] [PubMed] [Google Scholar]
  20. Ohsawa H., Kanatsuka A., Yamaguchi T., Makino H., Yoshida S. Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun. 1989 Apr 28;160(2):961–967. doi: 10.1016/0006-291x(89)92529-1. [DOI] [PubMed] [Google Scholar]
  21. Pacini G., Bergman R. N. MINMOD: a computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed. 1986 Oct;23(2):113–122. doi: 10.1016/0169-2607(86)90106-9. [DOI] [PubMed] [Google Scholar]
  22. Prager R., Wallace P., Olefsky J. M. In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects. J Clin Invest. 1986 Aug;78(2):472–481. doi: 10.1172/JCI112599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sanke T., Hanabusa T., Nakano Y., Oki C., Okai K., Nishimura S., Kondo M., Nanjo K. Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1991 Feb;34(2):129–132. doi: 10.1007/BF00500385. [DOI] [PubMed] [Google Scholar]
  24. Schmitz O. Effects of physiologic and supraphysiologic hyperglycemia on early and late-phase insulin secretion in chronically dialyzed uremic patients. Acta Endocrinol (Copenh) 1989 Aug;121(2):251–258. doi: 10.1530/acta.0.1210251. [DOI] [PubMed] [Google Scholar]
  25. Sowa R., Sanke T., Hirayama J., Tabata H., Furuta H., Nishimura S., Nanjo K. Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia. 1990 Feb;33(2):118–120. doi: 10.1007/BF00401051. [DOI] [PubMed] [Google Scholar]
  26. Westermark P., Wernstedt C., Wilander E., Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun. 1986 Nov 14;140(3):827–831. doi: 10.1016/0006-291x(86)90708-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES